memantine has been researched along with Cognitive Decline in 58 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " This trial examined the feasibility, tolerability, acceptability, and preliminary effects of memantine to prevent cognitive decline during chemotherapy for breast cancer." | 9.69 | A phase II single-arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effects. ( Abdou, Y; Ahles, TA; Carey, LA; Copeland, A; Deal, AM; Dees, EC; Heiling, HM; Jolly, TA; Joseph, R; Lopez, YE; McNamara, MA; Muss, HB; Nakamura, ZM; Nyrop, KA; O'Hare Kelly, E; Olajide, OA; Park, EM; Quillen, LJ; Rauch, JK; Ray, EM; Reeder-Hayes, KE; Stanton, KE, 2023) |
| "In the 1-year extension phase the favourable effect of adjunctive memantine on memory was sustained and we observed further improvement of negative, positive and overall symptoms in patients with clozapine-treated refractory schizophrenia." | 9.24 | Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study. ( de Haan, L; Deijen, JB; Schulte, PF; Veerman, SR, 2017) |
| "In patients with clozapine-treated refractory schizophrenia, memantine addition significantly improved verbal and visual memory and negative symptoms without serious adverse effects." | 9.22 | Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. ( de Haan, L; Schulte, PF; Smith, JD; Veerman, SR, 2016) |
| "Similar to observational studies, many participants in AD clinical trials receiving ChEIs or memantine experience greater cognitive decline." | 8.98 | Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis. ( Cutter, GR; Fowler, ME; Kennedy, RE; Schneider, LS, 2018) |
| "we made animal models in the natural environment of the Qinghai-Tibet Plateau at an altitude of 4300 m, and used animal behavior, morphology, molecular biology and other methods to evaluate the impact of chronic hypoxia exposure on cognitive function and the neuroprotective effect of Memantine." | 8.02 | Memantine ameliorates cognitive impairment induced by exposure to chronic hypoxia environment at high altitude by inhibiting excitotoxicity. ( Ge, RL; Ji, W; Liu, J; Luo, J; Wan, Y; Zhang, Y, 2021) |
| " This trial examined the feasibility, tolerability, acceptability, and preliminary effects of memantine to prevent cognitive decline during chemotherapy for breast cancer." | 5.69 | A phase II single-arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effects. ( Abdou, Y; Ahles, TA; Carey, LA; Copeland, A; Deal, AM; Dees, EC; Heiling, HM; Jolly, TA; Joseph, R; Lopez, YE; McNamara, MA; Muss, HB; Nakamura, ZM; Nyrop, KA; O'Hare Kelly, E; Olajide, OA; Park, EM; Quillen, LJ; Rauch, JK; Ray, EM; Reeder-Hayes, KE; Stanton, KE, 2023) |
| "Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection." | 5.56 | Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. ( Grieb, P; Rejdak, K, 2020) |
| "Sporadic cerebral amyloid angiopathy (CAA) is characterized by cerebrovascular amyloid beta (Aβ) deposits and causes cerebral hemorrhages and dementia in elderly people." | 5.51 | Memantine, a Noncompetitive N-Methyl-D-Aspartate Receptor Antagonist, Attenuates Cerebral Amyloid Angiopathy by Increasing Insulin-Degrading Enzyme Expression. ( Ando, Y; Inoue, Y; Masuda, T; Misumi, Y; Ueda, M; Yamashita, T, 2019) |
| "In the 1-year extension phase the favourable effect of adjunctive memantine on memory was sustained and we observed further improvement of negative, positive and overall symptoms in patients with clozapine-treated refractory schizophrenia." | 5.24 | Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study. ( de Haan, L; Deijen, JB; Schulte, PF; Veerman, SR, 2017) |
| " Studies in early radiotherapy treatment phase (five studies) Pharmacological studies in the "early radiotherapy treatment phase" were designed to prevent or ameliorate cognitive deficits and included drugs used in dementia (memantine) and fatigue (d-threo-methylphenidate hydrochloride)." | 5.22 | Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation. ( Brown, PD; Day, J; Gehring, K; Grosshans, D; Kirkman, MA; Li, J; Taphoorn, M; Zienius, K, 2022) |
| "In patients with clozapine-treated refractory schizophrenia, memantine addition significantly improved verbal and visual memory and negative symptoms without serious adverse effects." | 5.22 | Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. ( de Haan, L; Schulte, PF; Smith, JD; Veerman, SR, 2016) |
| "Similar to observational studies, many participants in AD clinical trials receiving ChEIs or memantine experience greater cognitive decline." | 4.98 | Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis. ( Cutter, GR; Fowler, ME; Kennedy, RE; Schneider, LS, 2018) |
| "we made animal models in the natural environment of the Qinghai-Tibet Plateau at an altitude of 4300 m, and used animal behavior, morphology, molecular biology and other methods to evaluate the impact of chronic hypoxia exposure on cognitive function and the neuroprotective effect of Memantine." | 4.02 | Memantine ameliorates cognitive impairment induced by exposure to chronic hypoxia environment at high altitude by inhibiting excitotoxicity. ( Ge, RL; Ji, W; Liu, J; Luo, J; Wan, Y; Zhang, Y, 2021) |
| "Wistar Rats were divided into six groups; control; HFCD; HFCD and Memantine; HFCD and Aliro (4, 8 and 16 mg/kg/week) to test for ability of Aliro to modulate cognitive impairment, amyloidosis, brain cholesterol homeostasis and neuro-inflammation in HFCD-induced-AD-like condition." | 4.02 | HMGB1/RAGE/TLR4 axis and glutamate as novel targets for PCSK9 inhibitor in high fat cholesterol diet induced cognitive impairment and amyloidosis. ( Abuelezz, SA; Hendawy, N, 2021) |
| "Mild cognitive impairment in Parkinson's disease (PD-MCI) is associated with an increased risk of cognitive decline." | 3.11 | Memantine for the patients with mild cognitive impairment in Parkinson's disease: a pharmacological fMRI study. ( Kawashima, S; Matsukawa, N, 2022) |
| "Early AD (eAD) includes mild cognitive impairment (MCI) due to AD and mild AD dementia." | 3.01 | Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease. ( Ballard, C; Garcia, MJ; Gsteiger, S; Lang, S; Leadley, R; Ross, J; Vinand, E, 2023) |
| " No withdrawal was observed due to the drugs' adverse effects." | 2.94 | Comparison of the efficacy and safety of melatonin and memantine in the alleviation of cognitive impairments induced by electroconvulsive therapy: A randomized clinical trial. ( Abbasinazari, M; Badri, T; Ghassab-Sahebkar, A; Keshvari, N; Qobadighadikolaei, R; Sarraf, N, 2020) |
| "One hundred and twenty patients with type 2 diabetes were examined and randomized into 4 groups: the computerized training group, the exercise therapy group, the akatinol memantine group and the control group." | 2.90 | [Different types of cognitive rehabilitation in patients with type 2 diabetes]. ( Matveeva, MV; Ratkina, KR; Samoilova, YG; Yakimovich, IY; Zhukova, NG, 2019) |
| "Many patients with brain cancer experience cognitive problems." | 2.61 | Interventions for cognitive problems in adults with brain cancer: A narrative review. ( Gehring, K; Klaver, KM; Schagen, SB; Sitskoorn, MM; van Lonkhuizen, PJC; Wefel, JS, 2019) |
| "Kynurenic acid (KYNA) is an antagonist to the α-7nACh and NMDA receptors." | 2.58 | Galantamine-Memantine Combination for Cognitive Impairments Due to Electroconvulsive Therapy, Traumatic Brain Injury, and Neurologic and Psychiatric Disorders: Kynurenic Acid and Mismatch Negativity Target Engagement. ( Koola, MM, 2018) |
| " Based on these studies, donepezil has been shown to be effective and safe in Chinese AD patients and may impact AD biomarkers, such as hippocampal atrophy, Aβ, and tau." | 2.58 | Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients. ( Gordon, ML; Zhang, N, 2018) |
| "Memantine is an uncompetitive N-methyl-d-aspartic acid receptor antagonist and is approved for the management of moderate-to-severe AD." | 2.53 | Pharmacotherpy and Alzheimer's Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach. ( Daulatzai, MA, 2016) |
| "Parkinson's disease is the second most frequent neurodegenerative disorder." | 2.52 | Cognitive impairment in Parkinson's disease. ( Ransmayr, G, 2015) |
| "Silibinin administration restored these mitochondrial disorders, as expected for the protection against MPTP injury." | 1.62 | Oral Administration of Silibinin Ameliorates Cognitive Deficits of Parkinson's Disease Mouse Model by Restoring Mitochondrial Disorders in Hippocampus. ( Fu, J; Fujisaki, H; Hattori, S; Hayashi, T; Ikejima, T; Liu, W; Liu, X; Mizuno, K; Song, S; Wang, C, 2021) |
| "Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection." | 1.56 | Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. ( Grieb, P; Rejdak, K, 2020) |
| "Sporadic cerebral amyloid angiopathy (CAA) is characterized by cerebrovascular amyloid beta (Aβ) deposits and causes cerebral hemorrhages and dementia in elderly people." | 1.51 | Memantine, a Noncompetitive N-Methyl-D-Aspartate Receptor Antagonist, Attenuates Cerebral Amyloid Angiopathy by Increasing Insulin-Degrading Enzyme Expression. ( Ando, Y; Inoue, Y; Masuda, T; Misumi, Y; Ueda, M; Yamashita, T, 2019) |
| "Memantine NPs were suitable for Alzheimer's disease and more effective than the free drug." | 1.48 | Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization. ( Calpena, AC; Camins, A; Cano, A; Carmona, N; Egea, MA; Espina, M; Ettcheto, M; García, ML; Sánchez-López, E; Silva, AM; Souto, EB, 2018) |
| "Overall, worsening and disease progression as measured by the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog), Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) and Clinical Dementia Rating (CDR) did not correlate with the duration of AChE-I treatment." | 1.48 | Correlation of CSF- and MRI-Biomarkers and Progression of Cognitive Decline in an Open Label MCI Trial. ( Bauer, C; Frölich, L; Heuser, I; Joachim, LK; Kornhuber, J; Maier, W; Peters, O; Rüther, E; Wiltfang, J, 2018) |
| "In the amnestic mild cognitive impairment subsample (n = 22), the conversion rate was 4." | 1.43 | Combined treatment with memantine/es-citalopram for older depressed patients with cognitive impairment: a pilot study. ( D'Antonio, K; Devanand, DP; Harper, OL; Marder, K; Pelton, GH; Roose, SP, 2016) |
| "The use and type of medication in Alzheimer's disease (AD) patients and association with falls is limited." | 1.40 | Medication for Alzheimer's disease and associated fall hazard: a retrospective cohort study from the Alzheimer's Disease Neuroimaging Initiative. ( Epstein, NU; Farlow, MR; Fisher, M; Guo, R; Singh, JP, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 34 (58.62) | 24.3611 |
| 2020's | 24 (41.38) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, WY | 1 |
| Feng, XL | 1 |
| Lu, D | 1 |
| Gao, H | 1 |
| Yu, Y | 1 |
| Yao, XS | 1 |
| Washida, K | 1 |
| Kitajima, E | 1 |
| Tanaka, T | 1 |
| Ikeda, S | 1 |
| Chiba, T | 1 |
| Noda, K | 1 |
| Yoshimoto, T | 1 |
| Fukuma, K | 1 |
| Saito, S | 1 |
| Ihara, M | 1 |
| Shi, X | 1 |
| Ren, G | 1 |
| Cui, Y | 1 |
| Xu, Z | 1 |
| Zeng, Y | 1 |
| Wang, L | 1 |
| Zhou, Y | 2 |
| Liang, M | 1 |
| Yu, J | 1 |
| Wu, S | 1 |
| Kawashima, S | 1 |
| Matsukawa, N | 1 |
| Companys-Alemany, J | 1 |
| Turcu, AL | 1 |
| Schneider, M | 1 |
| Müller, CE | 1 |
| Vázquez, S | 1 |
| Griñán-Ferré, C | 1 |
| Pallàs, M | 1 |
| Nguyen, HD | 1 |
| Perlett, L | 3 |
| Smith, EE | 3 |
| Garcia, MJ | 3 |
| Leadley, R | 3 |
| Lang, S | 3 |
| Ross, J | 3 |
| Vinand, E | 3 |
| Ballard, C | 3 |
| Gsteiger, S | 3 |
| Kirkman, MA | 3 |
| Day, J | 3 |
| Gehring, K | 4 |
| Zienius, K | 3 |
| Grosshans, D | 3 |
| Taphoorn, M | 3 |
| Li, J | 3 |
| Brown, PD | 3 |
| Qaid, EYA | 2 |
| Abdullah, Z | 2 |
| Zakaria, R | 2 |
| Long, I | 2 |
| Anderson, A | 1 |
| Malone, M | 1 |
| Nakamura, ZM | 1 |
| Deal, AM | 1 |
| Park, EM | 1 |
| Stanton, KE | 1 |
| Lopez, YE | 1 |
| Quillen, LJ | 1 |
| O'Hare Kelly, E | 1 |
| Heiling, HM | 1 |
| Nyrop, KA | 1 |
| Ray, EM | 1 |
| Dees, EC | 1 |
| Reeder-Hayes, KE | 1 |
| Jolly, TA | 1 |
| Carey, LA | 1 |
| Abdou, Y | 1 |
| Olajide, OA | 1 |
| Rauch, JK | 1 |
| Joseph, R | 1 |
| Copeland, A | 1 |
| McNamara, MA | 1 |
| Ahles, TA | 1 |
| Muss, HB | 1 |
| Zohny, SM | 1 |
| Habib, MZ | 1 |
| Mohamad, MI | 1 |
| Elayat, WM | 1 |
| Elhossiny, RM | 1 |
| El-Salam, MFA | 1 |
| Hassan, GAM | 1 |
| Aboul-Fotouh, S | 1 |
| Guan, X | 1 |
| Wang, J | 1 |
| Sun, Y | 1 |
| Wei, YJ | 1 |
| Xing, Y | 1 |
| Matveeva, MV | 1 |
| Samoilova, YG | 1 |
| Zhukova, NG | 1 |
| Ratkina, KR | 1 |
| Yakimovich, IY | 1 |
| Wang, QJ | 1 |
| Shen, YE | 1 |
| Wang, X | 1 |
| Fu, S | 1 |
| Zhang, X | 1 |
| Zhang, YN | 1 |
| Wang, RT | 1 |
| Sarraf, N | 1 |
| Badri, T | 1 |
| Keshvari, N | 1 |
| Ghassab-Sahebkar, A | 1 |
| Qobadighadikolaei, R | 1 |
| Abbasinazari, M | 1 |
| Amidzic, A | 1 |
| Tiro, N | 1 |
| Rejdak, K | 1 |
| Grieb, P | 1 |
| Ji, W | 1 |
| Zhang, Y | 1 |
| Luo, J | 1 |
| Wan, Y | 1 |
| Liu, J | 1 |
| Ge, RL | 1 |
| D'Onofrio, G | 1 |
| Nabavi, SM | 1 |
| Sancarlo, D | 1 |
| Greco, A | 1 |
| Pieretti, S | 1 |
| Abuelezz, SA | 1 |
| Hendawy, N | 1 |
| Sloley, SS | 1 |
| Main, BS | 1 |
| Winston, CN | 1 |
| Harvey, AC | 1 |
| Kaganovich, A | 1 |
| Korthas, HT | 1 |
| Caccavano, AP | 1 |
| Zapple, DN | 1 |
| Wu, JY | 1 |
| Partridge, JG | 1 |
| Cookson, MR | 1 |
| Vicini, S | 1 |
| Burns, MP | 1 |
| Liu, X | 2 |
| Wang, C | 1 |
| Liu, W | 1 |
| Song, S | 1 |
| Fu, J | 1 |
| Hayashi, T | 1 |
| Mizuno, K | 1 |
| Hattori, S | 1 |
| Fujisaki, H | 1 |
| Ikejima, T | 1 |
| Li, P | 1 |
| Xu, J | 1 |
| Gu, H | 1 |
| Peng, H | 1 |
| Yin, Y | 1 |
| Zhuang, J | 1 |
| Ilhan Algin, D | 1 |
| Dagli Atalay, S | 1 |
| Ozkan, S | 1 |
| Ozbabalik Adapinar, D | 1 |
| Ak Sivrioz, I | 1 |
| Koola, MM | 2 |
| Sklar, J | 1 |
| Davis, W | 1 |
| Nikiforuk, A | 1 |
| Meissen, JK | 1 |
| Sawant-Basak, A | 1 |
| Aaronson, ST | 1 |
| Kozak, R | 1 |
| Ghaffary, S | 1 |
| Ghaeli, P | 1 |
| Talasaz, AH | 1 |
| Karimi, A | 1 |
| Noroozian, M | 1 |
| Salehiomran, A | 1 |
| Jalali, A | 1 |
| Li, T | 1 |
| Luo, Z | 1 |
| Liu, Y | 1 |
| Wang, M | 1 |
| Yu, X | 1 |
| Cao, C | 1 |
| Liao, Z | 1 |
| Ding, Y | 1 |
| Yue, S | 1 |
| Sánchez-López, E | 1 |
| Ettcheto, M | 1 |
| Egea, MA | 1 |
| Espina, M | 1 |
| Cano, A | 1 |
| Calpena, AC | 1 |
| Camins, A | 1 |
| Carmona, N | 1 |
| Silva, AM | 1 |
| Souto, EB | 1 |
| García, ML | 1 |
| Kantrowitz, JT | 1 |
| Swerdlow, NR | 1 |
| Dunn, W | 1 |
| Vinogradov, S | 1 |
| Joachim, LK | 1 |
| Frölich, L | 2 |
| Rüther, E | 2 |
| Wiltfang, J | 1 |
| Maier, W | 2 |
| Kornhuber, J | 2 |
| Bauer, C | 1 |
| Heuser, I | 2 |
| Peters, O | 2 |
| Zhang, N | 1 |
| Gordon, ML | 1 |
| Torrez, VR | 1 |
| Zimmer, ER | 1 |
| Kalinine, E | 1 |
| Haas, CB | 1 |
| Zenki, KC | 1 |
| Muller, AP | 1 |
| Souza, DO | 1 |
| Portela, LV | 1 |
| Huisa, BN | 1 |
| Thomas, RG | 1 |
| Jin, S | 1 |
| Oltersdorf, T | 1 |
| Taylor, C | 1 |
| Feldman, HH | 1 |
| Kennedy, RE | 1 |
| Cutter, GR | 1 |
| Fowler, ME | 1 |
| Schneider, LS | 1 |
| Uribe, E | 1 |
| Fernández, L | 2 |
| Pacheco, D | 1 |
| Nayadoleni, N | 1 |
| Eblen-Zajjur, A | 1 |
| van Lonkhuizen, PJC | 1 |
| Klaver, KM | 1 |
| Wefel, JS | 1 |
| Sitskoorn, MM | 1 |
| Schagen, SB | 1 |
| von Arnim, CAF | 1 |
| Bartsch, T | 1 |
| Jacobs, AH | 1 |
| Holbrook, J | 1 |
| Bergmann, P | 1 |
| Zieschang, T | 1 |
| Polidori, MC | 1 |
| Dodel, R | 1 |
| Inoue, Y | 1 |
| Ueda, M | 1 |
| Masuda, T | 1 |
| Misumi, Y | 1 |
| Yamashita, T | 1 |
| Ando, Y | 1 |
| Tifratene, K | 1 |
| Sakarovitch, C | 1 |
| Rouis, A | 1 |
| Pradier, C | 1 |
| Robert, P | 1 |
| Tricco, AC | 1 |
| Soobiah, C | 1 |
| Berliner, S | 1 |
| Ho, JM | 1 |
| Ng, CH | 1 |
| Ashoor, HM | 1 |
| Chen, MH | 1 |
| Hemmelgarn, B | 1 |
| Straus, SE | 1 |
| Sonali, N | 1 |
| Tripathi, M | 1 |
| Sagar, R | 1 |
| Velpandian, T | 1 |
| Subbiah, V | 1 |
| Epstein, NU | 1 |
| Guo, R | 1 |
| Farlow, MR | 1 |
| Singh, JP | 1 |
| Fisher, M | 1 |
| Aprahamian, I | 1 |
| Stella, F | 1 |
| Forlenza, OV | 1 |
| Klich-Rączka, A | 1 |
| Piotrowicz, K | 1 |
| Mossakowska, M | 1 |
| Skalska, A | 1 |
| Wizner, B | 1 |
| Broczek, K | 1 |
| Wieczorowska-Tobis, K | 1 |
| Grodzicki, T | 1 |
| Pelton, GH | 1 |
| Harper, OL | 1 |
| Roose, SP | 1 |
| Marder, K | 1 |
| D'Antonio, K | 1 |
| Devanand, DP | 1 |
| Ransmayr, G | 1 |
| Daulatzai, MA | 1 |
| Yang, JC | 1 |
| Rodriguez, A | 1 |
| Royston, A | 1 |
| Niu, YQ | 1 |
| Avar, M | 1 |
| Brill, R | 1 |
| Simon, C | 1 |
| Grigsby, J | 1 |
| Hagerman, RJ | 1 |
| Olichney, JM | 1 |
| Veerman, SR | 2 |
| Schulte, PF | 2 |
| Smith, JD | 1 |
| de Haan, L | 2 |
| Deijen, JB | 1 |
| Kalemenev, SV | 1 |
| Zubareva, OE | 1 |
| Sizov, VV | 1 |
| Lavrent'eva, VV | 1 |
| Lukomskaya, NY | 1 |
| Kim, KK | 1 |
| Zaitsev, AV | 1 |
| Magazanik, LG | 1 |
| Cheng, J | 1 |
| Cao, L | 1 |
| Zhang, T | 1 |
| Li, H | 1 |
| Lin, W | 1 |
| Lorenz, D | 1 |
| Fesche, A | 1 |
| Schmidtke, K | 1 |
| Hüll, M | 1 |
| Perneczky, R | 1 |
| Möller, HJ | 1 |
| Jessen, F | 1 |
| Jahn, H | 1 |
| Luckhaus, C | 1 |
| Gertz, HJ | 1 |
| Schröder, J | 1 |
| Pantel, J | 1 |
| Teipel, S | 1 |
| Wellek, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Proof-of Concept Trial of Galantamine and Memantine for Cognitive Impairments in Schizophrenia: Is the Combination Effective?[NCT02234752] | Phase 2 | 3 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to Funding no longer available and PI no longer working at the institution) | ||
| Investigation of Factors Associated With Cognitive Status in the Elderly[NCT05051319] | 814 participants (Actual) | Observational [Patient Registry] | 2017-04-01 | Completed | |||
| Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment[NCT01876823] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome measure will be the change in level of cognition as measured by the MATRICS Consensus Cognitive Battery (MCCB). In schizophrenia, usual composite scores are 20-39. In healthy controls, usual composite scores are normalized to 40-60. Higher values of composite scores mean better cognition. Test scores are normalized to healthy controls, therefore no min-max range is available. Final scores calculated by MATRICS Consensus Cognitive Battery software. Exact minimum/maximum are not known to provider. Overall composite scores are reported. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | units on a scale (Number) | ||||
|---|---|---|---|---|---|
| Baseline Participant 1 | Week 6 Participant 1 | Baseline Participant 2 | Week 6 Participant 2 | Baseline Participant 3 | |
| Galantamine ER, Memantine XR | 48 | 48 | 32 | 25 | 9 |
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | µM (Mean) | ||||
|---|---|---|---|---|---|
| Baseline tryptophan Participant 1 | Week-6 tryptophan Participant 1 | Baseline tryptophan Participant 2 | Week-6 tryptophan Participant 2 | Baseline tryptophan Participant 3 | |
| KP Metabolites Values | 51.94 | 55.72 | 32.17 | 24.96 | 35.07 |
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. AUC ratio reported. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | AUC Ratio (Number) | ||||
|---|---|---|---|---|---|
| Baseline KYN/TRP Participant 1 | Week-6 KYN/TRP Participant 1 | Baseline KYN/TRP Participant 2 | Week-6 KYN/TRP Participant 2 | Baseline KYN/TRP Participant 3 | |
| KP Metabolites Values | 1.21 | 1.31 | 1.06 | 0.8 | 0.79 |
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. AUC ratio reported. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | AUC Ratio (Number) | ||||
|---|---|---|---|---|---|
| Baseline KYNA/KYN Participant 1 | Week-6 KYNA/KYN Participant 1 | Baseline KYNA/KYN Participant 2 | Week-6 KYNA/KYN Participant 2 | Baseline KYNA/KYN Participant 3 | |
| KP Metabolites Values | 0.075 | 0.050 | 0.121 | 0.114 | 0.152 |
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. MS* AUC is mass spectrometry times area under the curve. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | MS* AUC (Mean) | ||||
|---|---|---|---|---|---|
| Baseline KYNA Participant 1 | Week-6 KYNA Participant 1 | Baseline KYNA Participant 2 | Week-6 KYNA Participant 2 | Baseline KYNA Participant 3 | |
| KP Metabolites Values | 103911 | 83737 | 95139 | 73280 | 93163 |
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | µM (Mean) | ||||
|---|---|---|---|---|---|
| Baseline KYN Participant 1 | Week-6 KYN Participant 1 | Baseline KYN Participant 2 | Week-6 KYN Participant 2 | Baseline KYN Participant 3 | |
| KP Metabolites Values | 1.62 | 1.85 | 0.86 | 0.71 | 0.76 |
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. AUC ratio reported. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | AUC Ratio (Number) | ||||
|---|---|---|---|---|---|
| Baseline PIC/KYN Participant 1 | Week-6 PIC/KYN Participant 1 | Baseline PIC/KYN Participant 2 | Week-6 PIC/KYN Participant 2 | Baseline PIC/KYN Participant 3 | |
| KP Metabolites Values | 0.0317 | 0.0175 | 0.1039 | 0.0989 | 0.0655 |
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. MS* AUC is mass spectrometry times area under the curve. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | MS* AUC (Mean) | ||||
|---|---|---|---|---|---|
| Baseline PIC Participant 1 | Week-6 PIC Participant 1 | Baseline PIC Participant 2 | Week-6 PIC Participant 2 | Baseline PIC Participant 3 | |
| KP Metabolites Values | 44021 | 29542 | 81883 | 63745 | 40189 |
Change in 24-item Hamilton Rating Scale for Depression (HAMD) scores from baseline to Week 48: HAMD measures depression severity based on a series of 24 items items. The range of HAMD total score is 0-74; 0 indicates no depressive symptoms and a maximum HAMD score is a 74, where the greater the score indicates more significant psychopathology. In this study, moderate to severe depression is considered a HAMD-24 greater than 14. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | scores on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | -15.2 |
Change in Selective Reminding Test-Delayed Recall scores from baseline to Week 48: SRT Delay is administered 15 minutes after the immediate recall portion. Patients are asked to remember as many of the words as they can from the 6 trials. Maximum raw score is a 12 for free recall. If a patient is unable to recall a word, they are given a chance to recognize it among three incorrect word choices. Maximum raw score for recognition is 12. The greater the score on the delayed recall portion, the better the patient does on the assessment. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 1.2 |
Change in Selective Reminding Test-Total Immediate Recall (SRT-IR) scores from baseline to Week 48: Measures word recall (maximum 12 words per trial, across 6 trials). Maximum total recall score across 6 trials is 72; minimum recall is 0 across 6 trials. The higher the raw score, the better the patient did at recalling the target words. The unit of measure is the raw score, or the sum of the number of words recalled across all 6 trials. (NCT01876823)
Timeframe: baseline, 48 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 7.5 |
Change in Trails A scores from baseline to Week 48: Measures attention and executive function. It asks patients to connect numbers from 1-25 in numerical order as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | seconds (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 1.9 |
Change from baseline to Week 48 on Trails B: Measures attention and executive function. It asks patients to connect numbers and letters in numerical to alphabetical order from (1-13 and A-L) as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers and letters, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | seconds (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | -36.3 |
Change in Wechsler Memory Scale-III scores from baseline to Week 48: The WMS-III Visual Reproduction sub-test was used to measure visual working memory and delayed memory. Patients were shown pictures of four drawings and were asked to reproduce them from memory immediately after seeing them, and 25 minutes after seeing them. The four scores are summed and the greater the total raw score, the better the patient did on the assessment. The maximum raw score for this test is a 41 on both the immediate and delayed portions (the overall range is 0-82 points). The change score is calculated using the total scores of both the immediate and delayed portions. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 9.9 |
The CDR is a numeric rating scale that is used to quantify the severity of one's cognitive function. The scale goes from 0=normal; 0.5=mild cognitive impairment; 1 to 3=mild to moderate/severe dementia. CDR was used a dichotomous outcome measure (no=0; yes=1). (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | participants (Number) |
|---|---|
| Es-citalopram and Memantine Treatment | 1 |
The CGI Cognitive Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses from the entire group were calculated. Mean at final visit and baseline is reported below. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| CGI-Cognitive Change (Baseline) | Clinical Global Impression-Cogntive Change (WK 48) | |
| Es-citalopram and Memantine Treatment | 3.6 | 2.7 |
The CGI Depression Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses were calculated for the entire group. Mean at final visit has been reported below. Higher mean at baseline indicates a decrease in depression scores. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Cognitive Global Impression at Baseline | Cognitive Global Impression at Final Visit (WK 48) | |
| Es-citalopram and Memantine Treatment | 4.1 | 2.1 |
"Somatic side effect rating scale which includes 26 common somatic side effects associated with previous medication clinical trials; rated by the study physician. Factors were dichotomized to yes or no responses on this scale, which equated to the symptom being either present or not present. Yes and no responses were given a value of 0 (no) or 1 (yes). Responses from the entire group were calculated and the mean at baseline and the last visit is reported below." (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Treatment Emergent Side Effects (Baseline) | Treatment Emergent Side Effects (WK 48) | |
| Es-citalopram and Memantine Treatment | 6.6 | 3.2 |
15 reviews available for memantine and Cognitive Decline
| Article | Year |
|---|---|
Comparative Efficacy and Acceptability of Cholinesterase Inhibitors and Memantine Based on Dosage in Patients with Vascular Cognitive Impairment: A Network Meta-analysis.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Galantamine; Humans; | 2022 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Topics: Alzheimer Disease; Animals; Cognitive Dysfunction; Crocus; Donepezil; Humans; Memantine | 2021 |
Galantamine-Memantine Combination for Cognitive Impairments Due to Electroconvulsive Therapy, Traumatic Brain Injury, and Neurologic and Psychiatric Disorders: Kynurenic Acid and Mismatch Negativity Target Engagement.
Topics: Animals; Cognitive Dysfunction; Drug Therapy, Combination; Electroconvulsive Therapy; Galantamine; H | 2018 |
Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function.
Topics: Auditory Perception; Cognitive Dysfunction; Excitatory Amino Acid Agonists; Excitatory Amino Acid An | 2018 |
Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients.
Topics: Alzheimer Disease; China; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Humans; Meman | 2018 |
Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Dopami | 2018 |
Interventions for cognitive problems in adults with brain cancer: A narrative review.
Topics: Brain Neoplasms; Central Nervous System Stimulants; Cholinesterase Inhibitors; Cognition; Cognitive | 2019 |
Diagnosis and treatment of cognitive impairment.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Dementia; Humans; Memanti | 2019 |
Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis.
Topics: Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Galantamine; Humans; Indans; Memantine; | 2013 |
New treatment strategies for Alzheimer's disease: is there a hope?
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cognitive Dysfunction; Dementia | 2013 |
Cognitive impairment in Parkinson's disease.
Topics: Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Humans; Memantine; Muscle Rigidity; Par | 2015 |
Pharmacotherpy and Alzheimer's Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach.
Topics: Alzheimer Disease; Animals; Benzhydryl Compounds; Cognitive Dysfunction; Humans; Melatonin; Memantin | 2016 |
10 trials available for memantine and Cognitive Decline
| Article | Year |
|---|---|
Memantine for the patients with mild cognitive impairment in Parkinson's disease: a pharmacological fMRI study.
Topics: Cognitive Dysfunction; Humans; Magnetic Resonance Imaging; Memantine; Neuropsychological Tests; Park | 2022 |
A phase II single-arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effects.
Topics: Breast Neoplasms; Cognition; Cognitive Dysfunction; Feasibility Studies; Female; Humans; Memantine; | 2023 |
[Different types of cognitive rehabilitation in patients with type 2 diabetes].
Topics: Cognition; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Exercise Therapy; Humans; Memantine; Ne | 2019 |
Comparison of the efficacy and safety of melatonin and memantine in the alleviation of cognitive impairments induced by electroconvulsive therapy: A randomized clinical trial.
Topics: Adult; Aged; Cognition; Cognitive Dysfunction; Depressive Disorder, Major; Electroconvulsive Therapy | 2020 |
Memantine improves semantic memory in patients with amnestic mild cognitive impairment: A single-photon emission computed tomography study.
Topics: Aged; Amnesia; Cognitive Dysfunction; Demography; Female; Humans; Male; Memantine; Memory; Middle Ag | 2017 |
Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments.
Topics: Adolescent; Adult; Cognitive Dysfunction; Drug Therapy, Combination; Female; Galantamine; Humans; Ky | 2018 |
Memantine Improves Attentional Processes in Fragile X-Associated Tremor/Ataxia Syndrome: Electrophysiological Evidence from a Randomized Controlled Trial.
Topics: Aged; Ataxia; Attention; Cognitive Dysfunction; Drug Administration Schedule; Electroencephalography | 2016 |
Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognitive Dysfunction; Cross-Over Studies; Double-Blind Meth | 2016 |
Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognitive Dysfunction; Drug Resistance; Drug Synergism; Drug | 2017 |
A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI.
Topics: Aged; Alzheimer Disease; Amnesia; Cholinesterase Inhibitors; Cognition; Cognitive Dysfunction; Cohor | 2012 |
33 other studies available for memantine and Cognitive Decline
| Article | Year |
|---|---|
New lignans attenuating cognitive deterioration of Aβ transgenic flies discovered in Acorus tatarinowii.
Topics: Acorus; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Cognitive Dysfunction; Drosop | 2018 |
A Nationwide Multi-Center Questionnaire Survey on the Real-World State and Clinical Management of Poststroke Dementia in Japan.
Topics: Aged; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Donepezil; Female; Galantamine; Huma | 2021 |
NMDA receptor antagonists engender neuroprotection against gp120-induced cognitive dysfunction in rats through modulation of PKR activation, oxidative stress, ER stress and IRE1α signal pathway.
Topics: Animals; Apoptosis; Cognitive Dysfunction; Dementia; Endoplasmic Reticulum Stress; Endoribonucleases | 2022 |
NMDA receptor antagonists reduce amyloid-β deposition by modulating calpain-1 signaling and autophagy, rescuing cognitive impairment in 5XFAD mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Autophagy; Calpain; Cognitive Dysfunction; Female | 2022 |
Combination of Donepezil and Memantine Attenuated Cognitive Impairment Induced by Mixed Endocrine-Disrupting Chemicals: an In Silico Study.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Humans; Indans; Mema | 2022 |
Minocycline Protects Against Lipopolysaccharide-Induced Cognitive Impairment and Oxidative Stress: Possible Role of the CREB-BDNF Signaling Pathway.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cognitive Dysfunction; Cyclic AMP Response Element-Bindi | 2023 |
Minocycline Protects Against Lipopolysaccharide-Induced Cognitive Impairment and Oxidative Stress: Possible Role of the CREB-BDNF Signaling Pathway.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cognitive Dysfunction; Cyclic AMP Response Element-Bindi | 2023 |
Minocycline Protects Against Lipopolysaccharide-Induced Cognitive Impairment and Oxidative Stress: Possible Role of the CREB-BDNF Signaling Pathway.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cognitive Dysfunction; Cyclic AMP Response Element-Bindi | 2023 |
Minocycline Protects Against Lipopolysaccharide-Induced Cognitive Impairment and Oxidative Stress: Possible Role of the CREB-BDNF Signaling Pathway.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cognitive Dysfunction; Cyclic AMP Response Element-Bindi | 2023 |
The Differential Diagnosis and Treatment of Mild Cognitive Impairment and Alzheimer Disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Diagnosis, Differential; Diseas | 2022 |
Memantine/Aripiprazole Combination Alleviates Cognitive Dysfunction in Valproic Acid Rat Model of Autism: Hippocampal CREB/BDNF Signaling and Glutamate Homeostasis.
Topics: Animals; Aripiprazole; Autism Spectrum Disorder; Autistic Disorder; Brain-Derived Neurotrophic Facto | 2023 |
Cognitive impairment of MRL mice is related to NMDA receptor-mediated inflammatory response and production of adhesion molecules in MRL/lpr mice-derived micro-vascular endothelial cells.
Topics: Animals; Cognitive Dysfunction; Dexamethasone; E-Selectin; Endothelial Cells; Intercellular Adhesion | 2023 |
Vascular cognitive impairment associated with NOTCH3 Exon 33 mutation: A case report.
Topics: Cognitive Dysfunction; Dementia, Vascular; Donepezil; Humans; Male; Memantine; Middle Aged; Mutation | 2019 |
Concomitant memantine and
Topics: Alzheimer Disease; Animals; Animals, Genetically Modified; Biomarkers; Choline; Cognitive Dysfunctio | 2020 |
Kinking of Bilateral Internal Carotid Arteries as Cause of Cognitive Dysfunction.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Bosnia and Herzegovina; Bromazepam; Carotid Artery, | 2020 |
Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Amantadine; Asymptomatic Infections; Betacoronavirus; Co | 2020 |
Memantine ameliorates cognitive impairment induced by exposure to chronic hypoxia environment at high altitude by inhibiting excitotoxicity.
Topics: Altitude; Altitude Sickness; Alzheimer Disease; Animals; Cell Death; Cognition; Cognitive Dysfunctio | 2021 |
HMGB1/RAGE/TLR4 axis and glutamate as novel targets for PCSK9 inhibitor in high fat cholesterol diet induced cognitive impairment and amyloidosis.
Topics: Amyloidosis; Animals; Antibodies, Monoclonal, Humanized; Cholesterol; Cognitive Dysfunction; Diet, H | 2021 |
High-frequency head impact causes chronic synaptic adaptation and long-term cognitive impairment in mice.
Topics: Amyloid beta-Peptides; Animals; Behavior Rating Scale; Brain Injuries, Traumatic; Cognition; Cogniti | 2021 |
Oral Administration of Silibinin Ameliorates Cognitive Deficits of Parkinson's Disease Mouse Model by Restoring Mitochondrial Disorders in Hippocampus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; alpha-Synuclein; Animals; Apopto | 2021 |
Memantine ameliorates cognitive deficit in AD mice via enhancement of entorhinal-CA1 projection.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; CA1 Region, Hippocampal; Cognitive Dysfu | 2021 |
Effect of memantine on post-operative cognitive dysfunction after cardiac surgeries: a randomized clinical trial.
Topics: Aged; Cardiac Surgical Procedures; Cognitive Dysfunction; Drug Administration Schedule; Female; Huma | 2017 |
Excessive Activation of NMDA Receptors Induced Neurodevelopmental Brain Damage and Cognitive Deficits in Rats Exposed to Intrauterine Hypoxia.
Topics: Animals; Brain Injuries; Cognition; Cognition Disorders; Cognitive Dysfunction; Excitatory Amino Aci | 2018 |
Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antiparkinson Agents; Astro | 2018 |
Correlation of CSF- and MRI-Biomarkers and Progression of Cognitive Decline in an Open Label MCI Trial.
Topics: Activities of Daily Living; Amygdala; Amyloid beta-Peptides; Biomarkers; Cognitive Dysfunction; Dise | 2018 |
Memantine mediates astrocytic activity in response to excitotoxicity induced by PP2A inhibition.
Topics: Alzheimer Disease; Animals; Astrocytes; Cognitive Dysfunction; Glial Fibrillary Acidic Protein; Hipp | 2019 |
Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Drug T | 2019 |
Administration of memantine reverses behavioral, histological, and electrophysiological abnormalities in rats subjected to early maternal deprivation.
Topics: Animals; Animals, Newborn; Auditory Cortex; Behavior, Animal; Cognitive Dysfunction; Corpus Striatum | 2019 |
Memantine, a Noncompetitive N-Methyl-D-Aspartate Receptor Antagonist, Attenuates Cerebral Amyloid Angiopathy by Increasing Insulin-Degrading Enzyme Expression.
Topics: Amyloid beta-Peptides; Animals; Cerebral Amyloid Angiopathy; Cognitive Dysfunction; Insulysin; Maze | 2019 |
Mild cognitive impairment and anti-Alzheimer disease medications: A cross sectional study of the French National Alzheimer Databank (BNA).
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Antipsychotic Agents; Cognitive Dysfunction; Cross-S | 2014 |
Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer's disease.
Topics: Aged; Alleles; Alzheimer Disease; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; C | 2014 |
Medication for Alzheimer's disease and associated fall hazard: a retrospective cohort study from the Alzheimer's Disease Neuroimaging Initiative.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoprotein E4; Case-Contr | 2014 |
The assessment of cognitive impairment suspected of dementia in Polish elderly people: results of the population-based PolSenior Study.
Topics: Age Factors; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cognitive Dysfunction; Cohort Studi | 2014 |
Combined treatment with memantine/es-citalopram for older depressed patients with cognitive impairment: a pilot study.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Cognitive Dysfunction; Depressive Disord | 2016 |
Memantine attenuates cognitive impairments after status epilepticus induced in a lithium-pilocarpine model.
Topics: Animals; Cognition; Cognitive Dysfunction; Exploratory Behavior; Extinction, Psychological; Lithium; | 2016 |
Neo-adjuvant chemotherapy with cisplatin induces low expression of NMDA receptors and postoperative cognitive impairment.
Topics: Animals; Cisplatin; Cognition; Cognitive Dysfunction; Female; Hippocampus; Learning; Maze Learning; | 2017 |